Shreyaa Rohindra Lall, Niroj Kumar Sahoo, Nasiq Hasan, Sumit Randhir Singh, Arman Zarnegar, Stanley Saju, Jessica Cao, Charles C Wykoff, Lisa Checchin, Lorenzo Pili, Maurizio Battaglia Parodi, Lorenzo Ferro Desideri, Felicia Hertkorn, Marion R Munk, Halit Winter, Manjot K Gill, Carmen Antia Rodriguez-Fernandes, Luis Arias Barquet, Yusuf Ashfaq, Zachary Kroeger, Luiz H Lima, Giulia Gregori, Marco Lupidi, Priya Shah, Panisa Singhanetr, Elizabeth Rossin, Francisco J Rodriguez, Carol Villafeurte-Trisolini, Glenn Yiu, Bita Momenaei, Rosalind Ni, Sunir Garg, Timothy Y Y Lai, Min Kim, Naoya Imanaga, Hideki Koizumi, Michael G Zhang, Samer Khateb, Pernaut Chotcomwongse, Paisan Ruamviboonsuk, D Lihteh Wu, Jay Chhablani
Immune-mediated CSCR shows distinct structure-function profiles, with immune-mediated disease status independently associated with poorer visual outcomes and higher recurrence, while OCT-biomarkers predict functional and anatomic change.
PURPOSE: To assess the clinical course and imaging characteristics of central serous chorioretinopathy (CSCR) in patients with immune-mediated diseases and examine differences based on prior corticosteroid exposure.
DESIGN: Retrospective multicenter clinical cohort study from the Macula Society CSCR Study Group (MICRoN).
PARTICIPANTS: The study included 287 eyes of 267 patients with a diagnosis of CSCR.
METHODS: Baseline and follow-up best-recorded visual acuity (BRVA) along with multimodal imaging features including central macular thickness (CMT), subfoveal choroidal thickness (SFCT), neurosensory detachment (NSD) height, and extent of retinal pigment epithelium (RPE) alteration, were evaluated across groups defined by immune-mediated disease status and corticosteroid exposure. Multivariable regression models were used to assess the impact of the presence of immune-mediated pathologies and other baseline factors on visual outcomes, as well as disease persistence, recurrence, and resolution.
MAIN OUTCOMES: Longitudinal changes in BRVA and multimodal imaging parameters across CSCR subgroups stratified by presence of immune-mediated disease and corticosteroid exposure; factors associated with disease persistence, recurrence, and changes in BRVA.
RESULTS: The study included 287 eyes of 267 patients (mean age 48.3±10.8 years; 144 males, 123 females) across four groups: immune-mediated disease with steroids (47 eyes), steroids without immune-mediated disease (69 eyes), immune-mediated disease without steroids (62 eyes), and idiopathic CSCR (109 eyes). Steroid-exposed immune-mediated cases had worse baseline BRVA (0.3±0.4 vs 0.2±0.2 logMAR, p=0.03), greater NSD height, larger RPE alteration, and thinner choroidal parameters. On multivariable analysis, absence of immune-mediated disease predicted greater BRVA improvement (β=0.22, p=0.01) and immune-mediated disease predicted recurrence (OR 2.64, p=0.02). Larger RPE alteration predicted worse baseline BRVA (β=0.34, p=0.001), older age predicted lower resolution (OR 0.11, p=0.03), and multifocal lesions predicted greater logMAR change (β=0.23, p=0.007). At follow-up, CMT and SFCT decreased across all groups, though visual improvement and resolution rates remained lower in immune-mediated cohorts.
CONCLUSIONS: Immune-mediated CSCR shows distinct structure-function profiles, with immune-mediated disease status independently associated with poorer visual outcomes and higher recurrence, while OCT-biomarkers predict functional and anatomic change.